You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 5, 2024

Claims for Patent: 10,094,836

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,094,836

Title:	SLCO1B3 genotype
Abstract:	The invention relates methods of identifying and predicting inter-patient differences in prognostic prediction for survival in androgen independent prostate cancer. It further related to methods for determining and exploiting such differences to improve medical outcomes. Moreover, it provides methods for determining if a subject has prostate cancer.
Inventor(s):	Figg; William D. (Fairfax, VA), Sparreboom; Alex (Memphis, TN), Hamada; Akinobu (Tokyo, JP), Price; Douglas K. (Fairfax, VA), Sissung; Tristan M. (Annandale, VA)
Assignee:	The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC)
Application Number:	12/522,480
Patent Claims:	1. A method of treating a subject having prostate cancer comprising determining a SLCO1B3 genotype status of a subject having prostate cancer, wherein a homozygous 334GG and/or 699AA SLCO1B3 genotype is indicative of a subject that will respond to androgen-deprivation therapy, and wild-type SLCO1B3 genotype is indicative of a patient that is unresponsive to androgen-deprivation therapy; and treating the subject having wild-type SLCO1B3 genotype by discontinuing androgen-deprivation therapy and administering a therapeutically effective amount of an anti-neoplastic agent to the subject, thereby improving survival of the subject having wild-type SLCO1B3 genotype. 2. The method of claim 1, wherein the anti-neoplastic agent is selected from one or more of docetaxel, cisplatin, cyclophosphamide, doxorubicin, prednisone, 5-FU, trastuzumab, 3G4 travacin, gemcitabine, estramustine, carboplatin, mitomycin, capecitabine, irinotecan, topotecan, vinorelbine, ifosamide, epirubicin, imatinib, gefitinib, erlotinib, cetuximab, bevacizumab, thalidomide, or radiation. 3. The method of claim 1, wherein the anti-neoplastic agent is docetaxel.

Details for Patent 10,094,836

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998	⤷ Try a Trial	2027-01-08
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017	⤷ Try a Trial	2027-01-08
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004	⤷ Try a Trial	2027-01-08
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007	⤷ Try a Trial	2027-01-08
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004	⤷ Try a Trial	2027-01-08
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019	⤷ Try a Trial	2027-01-08
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.